Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Entera Bio Ltd. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 17 | 14 | −3 |
| Shares | 5.32M | 7.49M | +2.17M (+40.8%) |
| Value | $10.1M | $15.9M | +$5.79M (+57.3%) |
New holders (2)
Institutions that held Entera Bio Ltd. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Northern Trust Corp | 212,483 | $450.5K | 0.00% |
| Perigon Wealth Management, LLC | 145,843 | $325.2K | 0.01% |
Sold out (5)
Institutions that held Entera Bio Ltd. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| UBS Group AG | 142,747 | $271.2K |
| Citadel Advisors LLC | 20,553 | $39.1K |
| Advisor Group Holdings, Inc. | 16,777 | $30.2K |
| CIBC World Markets Inc. | 12,500 | $24.0K |
| JPMorgan Chase & Co | 2 | $4 |